Do PPARs play a role in cardiac hypertrophy and heart failure?

Drug Discovery Today: Disease Mechanisms

Volumn 2, Issue 1, 2005, Pages 109-114

  Tian, Qi ^a   Barger, Philip M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENOSINE TRIPHOSPHATE; ANGIOTENSIN II; CELL NUCLEUS RECEPTOR; FIBRIC ACID DERIVATIVE; GW 501516; ISOPROTEIN; L 165041; LIPID; LONG CHAIN FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIRINIXIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CARDIOMYOPATHY; DOWN REGULATION; DRUG TARGETING; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; FATTY ACID OXIDATION; HEART DISEASE; HEART FAILURE; HEART MUSCLE METABOLISM; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPID METABOLISM; METABOLIC SYNDROME X; MITOCHONDRION; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 33645048176     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2005.05.011     Document Type: Review

References (34)

1. S.A. Hunt et. al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary J. Am. Coll. Cardiol. 38 2001 2101-2113
2. G.A. Francis et. al. Nuclear receptors and the control of metabolism Annu. Rev. Physiol. 65 2003 261-311
3. O. Braissant et. al. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat Endocrinology 137 1996 354-366
4. P.M. Barger D.P. Kelly PPAR signaling in the control of cardiac energy metabolism Trends Cardiovasc. Med. 10 2000 238-245
5. F.M. Campbell et. al. A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels J. Biol. Chem. 277 2002 4098-4103
6. K. Watanabe et. al. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity J. Biol. Chem. 275 2000 22293-22299
7. T.C. Leone et. al. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: The PPARalpha-null mouse as a model of fatty acid oxidation disorders Proc. Natl. Acad. Sci. USA 96 1999 7473-7478
8. M.N. Sack et. al. A role for Sp and nuclear receptor transcription factors in a cardiac hypertrophic growth program Proc. Natl. Acad. Sci. USA 94 1997 6438-6443
9. J.J. Lehman D.P. Kelly Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth Heart Fail Rev. 7 2002 175-185
10. P.M. Barger et. al. Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth J. Clin. Invest. 105 2000 1723-1730
11. J.J. Lehman D.P. Kelly Transcriptional activation of energy metabolic switches in the developing and hypertrophied heart Clin. Exp. Pharmacol. Physiol. 29 2002 339-345
12. J.C. Osorio et. al. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure Circulation 106 2002 606-612
13. K. Ballal et. al. ERK MAPK regulation of cardiac retinoid X receptor is involved in impaired fatty acid beta-oxidation during hypertrophic growth Annual Meeting of American Heart Association 7-10 November 2004, New Orleans, LA, USA 2004 (Abstract 946)
14. T. Ogata et. al. Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts Clin. Sci. (Lond.) 103 Suppl. 48 2002 284S-288S
15. F. Liang et. al. Peroxisome proliferator activated receptor (PPAR)alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes Endocrinology 144 2003 4187-4194
16. M.E. Young et. al. Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart J. Biol. Chem. 276 2001 44390-44395
17. T. Ogata et. al. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway J. Am. Coll. Cardiol. 43 2004 1481-1488
18. B.N. Finck et. al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus J. Clin. Invest. 109 2002 121-130
19. B.N. Finck et. al. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: Modulation by dietary fat content Proc. Natl. Acad. Sci. USA 100 2003 1226-1231
20. E. Aasum et. al. Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator Am. J. Physiol. Heart. Circ. Physiol. 283 2002 H949-H957
21. J.M. Ye et. al. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: Comparison with PPAR-gamma activation Diabetes 50 2001 411-417
22. D.M. Muoio et. al. Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR delta J. Biol. Chem. 277 2002 26089-26097
23. T. Tanaka et. al. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome Proc. Natl. Acad. Sci. USA 100 2003 15924-15929
24. D. Holst et. al. Nutritional regulation and role of peroxisome proliferator-activated receptor delta in fatty acid catabolism in skeletal muscle Biochim. Biophys. Acta 1633 2003 43-50
25. A.J. Gilde et. al. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism Circ. Res. 92 2003 518-524
26. L. Cheng et. al. Peroxisome proliferator-activated receptor delta activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes Biochem. Biophys. Res. Commun. 313 2004 277-286
27. L. Cheng et. al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy Nat. Med. 10 2004 1245-1250
28. A. Planavila et. al. Peroxisome proliferator-activated receptor beta/ delta activation inhibits hypertrophy in neonatal rat cardiomyocytes Cardiovasc. Res. 65 2005 832-841
29. M.R. Mehrabi et. al. Quantitative analysis of peroxisome proliferator-activated receptor gamma (PPARgamma) expression in arteries and hearts of patients with ischaemic or dilated cardiomyopathy Eur. J. Heart Fail 5 2003 733-739
30. L. Wu et. al. Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats Am. J. Hypertens. 17 2004 749-756
31. K. Yamamoto et. al. Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes Circulation 104 2001 1670-1675
32. M. Asakawa et. al. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo Circulation 105 2002 1240-1246
33. C. Ward et. al. Prostaglandin D2 and its metabolites induce caspase-dependent granulocyte apoptosis that is mediated via inhibition of I kappa B alpha degradation using a peroxisome proliferator-activated receptor-gamma-independent mechanism J. Immunol. 168 2002 6232-6243
34. R.H. Unger Lipotoxic diseases Annu. Rev. Med. 53 2002 319-336